tissue plasminogen activator

(redirected from Alteplase)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.

tissue plasminogen activator

[¦tish·ü plaz‚min·ə·jən ′ak·tə‚vād·ər]
(medicine)
A proteolytic enzyme that can convert plasminogen to plasmin.
References in periodicals archive ?
Summary of alteplase thrombolysis cases at Baylor University Medical Center from January to November 1999 Patients Encounters Indication (No.
Plasma levels of plasminogen activator inhibitor type-1, [beta]-thromboglobulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with Alteplase.
Patients with stroke do not become poor candidates for alteplase when the clock strikes 4 hours," he said.
These data, collected in a real life clinical setting, suggest that patients who are treated with alteplase in accordance with the current European summary of product characteristics, but in an extended time window of treatment initiation between 3 and 4.
The rate of death or escalation of treatment was significantly lower in those who received alteplase (13 patients, 11%) than in those who received the placebo (34 patients, 24.
Kaste M, Fieschi C, et al: Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II).
Buchan, Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.
The medicinal product with active substance Alteplase - Activator plasminogen, rt-PA, ATC B01AD02.
Contract notice: Medication alteplase (b01ad02) and eptifibatide (b01ac16) buying.
Alteplase, Ampicillin, Azitromycinum, Ciprofloxacin, Clarithromycin, Colistimethatum natric.
Obtaining Medication: eptifibatide (B01AC16), alteplase (B01AD02), tranexamic acid (B02AA02), glyceryl trinitrate (C01DA02), protamine (V03AB14).
Building contracts are ongoing supply of medicinal products containing alteplase in the desired size, for a period of two years according to the current needs of the client.